D
David A. Cooper
Researcher at Pfizer
Publications - 965
Citations - 81765
David A. Cooper is an academic researcher from Pfizer. The author has contributed to research in topics: Acquired immunodeficiency syndrome (AIDS) & Viral load. The author has an hindex of 117, co-authored 903 publications receiving 69249 citations. Previous affiliations of David A. Cooper include Boston Children's Hospital & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.
A.I. Veldkamp,Gerrit Jan Weverling,Joep M. A. Lange,Julio S. G. Montaner,Peter Reiss,David A. Cooper,Stefano Vella,David A. Hall,Jos H. Beijnen,Richard M. W. Hoetelmans +9 more
TL;DR: A high exposure to nevirapine (in a twice daily regimen) is significantly associated with improved virological response in the short as well as in the long term, suggesting that optimization of ne virapine concentration might be used as a tool to improve virologic outcome in (antiretroviral-naive) patients treated with nevirAPine.
Journal ArticleDOI
Short-course antiretroviral therapy in primary HIV infection.
Sarah Fidler,Kholoud Porter,Fiona M. Ewings,John Frater,Gita Ramjee,David A. Cooper,Helen Rees,Martin Fisher,Martin T. Schechter,Pontiano Kaleebu,Giuseppe Tambussi,Sabine Kinloch,José M. Miró,Anthony D. Kelleher,Myra McClure,Steve Kaye,M Gabriel,Rodney E. Phillips,Jonathan Weber,Abdel Babiker +19 more
TL;DR: A 48-week course of ART in patients with primary HIV infection delayed disease progression, although not significantly longer than the duration of the treatment, and there was no evidence of adverse effects of ART interruption on the clinical outcome.
Journal ArticleDOI
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase
John M. Murray,Sean Emery,Anthony D. Kelleher,Matthew Law,Joshua Chen,Daria J. Hazuda,Bach-Yen Nguyen,Hedy Teppler,David A. Cooper +8 more
TL;DR: Plasma viral loads were 70% lower at initiation of second-phase decay for individuals taking raltegravir than for those taking efavirenz, challenging the current hypothesis that second- phase virus originates from infected long-lived cells, as an integrase inhibitor should not impact on viral production from this cell population.
Journal ArticleDOI
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials
Roy T. Steigbigel,David A. Cooper,Hedy Teppler,Joseph J. Eron,José M. Gatell,Princy Kumar,Jürgen K. Rockstroh,Mauro Schechter,Christine Katlama,Martin Markowitz,Patrick Yeni,Mona Loutfy,Adriano Lazzarin,Jeffrey L. Lennox,Bonaventura Clotet,Jing Zhao,Hong Wan,Rand R. Rhodes,Kim M. Strohmaier,Richard J. O. Barnard,Robin Isaacs,Bach-Yen Nguyen +21 more
TL;DR: Raltegravir (400 mg twice daily) plus optimized background therapy was generally well tolerated, with superior and durable antiretroviral and immunological efficacy, compared with optimizing background therapy alone.
Journal ArticleDOI
The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.
TL;DR: It is suggested that immunization with PCV13 has the potential to induce cross-protective responses to related serotypes not directly covered by the vaccine.